Elevated MS4A12 expression is indicative of resistance to concurrent chemoradiotherapy and inferior survival in patients with rectal cancer
MS4A12 expression may offer a helpful predictive and prognostic indicator for identifying patients who could gain advantages from neoadjuvant CCRT.
Authors
- Ching‐Chieh Yang (ORCID: https://orcid.org/0000-0003-3823-4673)
- Hong-Yue Lai (ORCID: https://orcid.org/0000-0002-6197-9828)
- Chih‐I Chen (ORCID: https://orcid.org/0000-0002-5311-6889)
- Pin-Chun Chen (ORCID: https://orcid.org/0000-0002-5764-1736)
- Wan‐Shan Li (ORCID: https://orcid.org/0000-0001-6679-4868)
- Yi-Kai Kao (ORCID: https://orcid.org/0000-0002-6399-7712)
- Yu-Jen Wang (ORCID: https://orcid.org/0009-0004-9243-8305)
- Po-Wen Yang
- Hsin-Hwa Tsai
Institutions
- Chung Hwa University of Medical Technology (TW)
- National Sun Yat-sen University (TW)
- China Medical University (TW)
- E-Da Hospital (TW)
- China Medical University Hospital (TW)
- Chi Mei Medical Center (TW)
- Chia Nan University of Pharmacy and Science (TW)
- I-Shou University (TW)
Publication Details
- Journal
- Radiation Oncology
- Published
- 2025-08-09
- DOI
- https://doi.org/10.1186/s13014-025-02709-5
- Primary Topic
- Glycosylation and Glycoproteins Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- China Medical University Hospital
- National Health Research Institutes
- China Medical University
- China Medical University, Taiwan
- National Science and Technology Council
- Division of Materials Research